GlassScriptPhysician profile
Swapna D Deo
NPI 1821053489
$4,564.01
in general payments reported to CMS, 2019-2025
28 companies · $553 in 2025
The $553 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,871 · 2020: $1,575 · 2022: $238 · 2023: $212 · 2024: $115 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $880.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $1,200.00 | 2020 | |
| Novo Nordisk INC | $505.52 | 2019-2020 | |
| Lilly USA, LLC | $286.69 | 2019-2022 | |
| Insulet Corporation | $270.64 | 2019-2025 | Omnipod, Omnipod |
| Medtronic, INC. | $262.28 | 2023-2025 | Minimed 780g |
| Janssen Pharmaceuticals, INC | $254.06 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $214.07 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.83 | 2019-2020 | |
| Dexcom, INC. | $151.96 | 2019-2023 | Dexcom G7 Gss (161) |
| Abbott Laboratories | $139.99 | 2019-2022 | |
| Medtronic Minimed, INC. | $139.25 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $131.00 | 2025 | |
| Ascendis Pharma Endocrinology INC | $124.70 | 2025 | Yorvipath |
| Amgen INC. | $118.94 | 2019 | |
| Shire North American Group INC | $110.57 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amryt Pharma Holdings LTD | $83.20 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $71.90 | 2019 | |
| Corcept Therapeutics | $43.92 | 2019 | |
| Abbvie INC. | $40.60 | 2019-2020 | |
| Amarin Pharma, INC. | $37.42 | 2019 | |
| Radius Health, INC. | $31.32 | 2019-2020 | |
| Ibsa Pharma INC. | $30.25 | 2019 | |
| Eisai INC. | $23.95 | 2019 | |
| Lifescan, INC. | $22.94 | 2019 | |
| Antares Pharma, INC. | $16.79 | 2020 | |
| Therapeuticsmd, INC. | $16.65 | 2019 | |
| Pfizer INC. | $12.80 | 2019 | |
| Merck Sharp & Dohme LLC | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swapna Deo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.